Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 9;13(5):89.
doi: 10.3390/ph13050089.

Exploring Kinase Inhibition Properties of 9 H-pyrimido[5,4- b]- and [4,5- b]indol-4-amine Derivatives

Affiliations

Exploring Kinase Inhibition Properties of 9 H-pyrimido[5,4- b]- and [4,5- b]indol-4-amine Derivatives

Yvonnick Loidreau et al. Pharmaceuticals (Basel). .

Abstract

We previously highlighted the interest in 6,5,6-fused tricyclic analogues of 4-aminoquinazolines as kinase inhibitors in the micromolar to the nanomolar range of IC50 values. For the generation of chemical libraries, the formamide-mediated cyclization of the cyanoamidine precursors was carried out under microwave irradiation in an eco-friendly approach. In order to explore more in-depth the pharmacological interest in such tricyclic skeletons, the central five member ring, i.e., thiophène or furan, was replaced by a pyrrole to afford 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine derivatives inspired from harmine. The inhibitory potency of the final products was determined against four protein kinases (CDK5/p25, CK1/ε, GSK3 and DYRK1A). As a result, we have identified promising compounds targeting CK1/ε and DYRK1A and displaying micromolar and submicromolar IC50 values.

Keywords: CDK5; CK1; DYRK1A; GSK-3; microwave-assisted chemistry; protein kinases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Previous benzo[b]thieno[3,2-d]pyrimidin-4-amines (A) and their pyrido (B) and pyrazino (C) analogues (left). The 9H-pyrimido[5,4-b]indol-4-amine derivatives (1 and 2) and their 9Hpyrimido[4,5-b]indole isomers (3 and 4) described in this work (right).
Scheme 1
Scheme 1
Synthesis of 9H-pyrimido[5,4-b]indol-4-amines (series 1ad and 2ad) and their 9H-pyrimido[4,5-b]indoles isomers (series 3ad and 4ad).
Scheme 2
Scheme 2
Microwave-assisted synthesis of N-alkylated harmine derivatives (compounds 11bd).
Figure 2
Figure 2
Comparison between selected pyrimido[4,5-b or 5,4-b]indol-4-amines described in this work and some of their thieno[2,3-d]pyrimidin-4-amine congeners (12, 13, 14 and 15) described in preceding work.

Similar articles

Cited by

References

    1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The Protein Kinase Complement of the Human Genome. Science. 2002;298:1912–1934. doi: 10.1126/science.1075762. - DOI - PubMed
    1. Ionescu A., Dufrasne F., Gelbcke M., Jabin I., Kiss R., Lamoral-Theys D. DYRK1A kinase inhibitors with emphasis on cancer. Mini Rev. Med. Chem. 2012;12:1315–1329. doi: 10.2174/138955712804586639. - DOI - PubMed
    1. Fernández-Martínez P., Zahonero C., Sánchez-Gómez P. DYRK1A: The double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol. Cell. Oncol. 2015;2:970048. doi: 10.4161/23723548.2014.970048. - DOI - PMC - PubMed
    1. Duchon A., Herault Y. DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome. Front. Behav. Neurosci. 2016;10:87. doi: 10.3389/fnbeh.2016.00104. - DOI - PMC - PubMed
    1. Branca C., Shaw D.M., Belfiore R., Gokhale V., Shaw A.Y., Foley C., Smith B., Hulme C., Dunckley T., Meechoovet B., et al. Dyrk1 inhibition improves Alzheimer’s disease-like pathology. Aging Cell. 2017;16:1146–1154. doi: 10.1111/acel.12648. - DOI - PMC - PubMed